[Disclosure] Celltrion (068270) Submits Application to Modify Phase 3 Clinical Trial Plan for ‘CT-P51’ (Keytruda Biosimilar) to the U.S. FDA

Fact Source: Financial Supervisory Service DART / 2026-07-06

Disclosure Type: Major Management Event Related to Investment Judgement

💡 3-Second Summary

Celltrion has officially submitted a clinical trial protocol modification request to the U.S. Food and Drug Administration (FDA) for the global Phase 3 clinical trial of CT-P51, its biosimilar candidate for the block-buster immunotherapy ‘Keytruda.’

📊 1. [Summary of Key Disclosure Content and Figures]

• Clinical Trial Phase & Target Indication: Global Phase 3 Clinical Trial / Non-Small Cell Lung Cancer
• Submission Date & Authority: July 6, 2026 (local time) / U.S. Food and Drug Administration (FDA)
• Clinical Trial Registration Number: EU CT number 2024-514048-98-00
• Clinical Trial Subjects: 220 patients
• Trial Method and Duration: Double-blind, randomized, active-controlled, Phase 3 study / Treatment duration of 2 years
• Clinical Trial Objective: To compare and evaluate the efficacy and safety of CT-P51 against the original drug Keytruda in previously untreated patients with metastatic non-squamous non-small cell lung cancer

📈 2. [Professional Insight: What This Disclosure Means for Investors]

• Mid-Course Clinical Protocol Adjustments: This modification targets the Phase 3 trial design that was previously approved by the U.S. FDA back in August 2024. Modifying an active protocol is generally a tactical move to optimize operational efficiency, patient recruitment criteria, or align with updated therapeutic guidelines. Note that the specific drivers behind this change were not provided in the official disclosure.
• FDA Review and Timeline Variances: Because the modification is subject to regulatory review and re-approval by the FDA, investors should expect potential minor adjustments to the overall clinical timeline. Ensuring that the regulatory body greenlights the changes without requesting supplementary data is crucial for keeping the development of this major pipeline on schedule.
• Inherent Risk Profile of Biologics Development: While Keytruda represents one of the largest market opportunities in oncology biosimilars, late-stage drug development carries massive high-risk hurdles. Statistically, the average probability of a clinical candidate receiving final market authorization is only around 10%. Any unexpected efficacy variance or adverse events during the clinical phases could alter or halt commercialization plans.

📝 Editor’s Comment (by K-STOCK Editor)

Targeting Keytruda—the world’s top-selling cancer therapy—is a massive undertaking for Celltrion. This latest disclosure reports a protocol modification request submitted to the U.S. FDA rather than a brand-new clinical trial milestone. While modifying active Phase 3 plans is a routine practice to optimize trial variables, it inevitably requires investors to wait for regulatory clearance before the modified protocol can be fully executed. Given that the probability of final clinical success is statistically capped near 10%, global market participants should maintain a balanced perspective. Instead of reacting to the filing of the amendment itself, it is safer to monitor the official FDA approval of the modified protocol and subsequent patient enrollment metrics.

📢 Disclaimer & Source Information

Source: This content has been structured and newly written based on official disclosure data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).

Investment Risk Advisory: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice, solicitation, or a recommendation to buy or sell any specific stock. All investment decisions and financial liabilities rest entirely with the individual investor.

Inquiries: For compliance queries or copyright-related requests, please contact us at ksb220805@gmail.com.